Home » Stocks » YMAB

Y-mAbs Therapeutics, Inc. (YMAB)

Stock Price: $44.92 USD -1.04 (-2.26%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 1.82B
Revenue (ttm) n/a
Net Income (ttm) -122.54M
Shares Out 40.19M
EPS (ttm) -3.10
PE Ratio n/a
Forward PE 31.35
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $44.92
Previous Close $45.96
Change ($) -1.04
Change (%) -2.26%
Day's Open 45.90
Day's Range 43.33 - 46.64
Day's Volume 253,467
52-Week Range 14.39 - 54.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com...

GlobeNewsWire - 3 weeks ago

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com...

Seeking Alpha - 1 month ago

Y-mAbs Therapeutics recently had its first approval. Its second drug, despite some hiccups, is on its way to the market.

Seeking Alpha - 1 month ago

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutra...

Other stocks mentioned: ABBV, ADCT, ALLO, BNTX, LEGN
GlobeNewsWire - 1 month ago

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com...

GlobeNewsWire - 1 month ago

NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused o...

GlobeNewsWire - 1 month ago

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and ...

Seeking Alpha - 2 months ago

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and ...

GlobeNewsWire - 3 months ago

NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and ...

PRNewsWire - 3 months ago

NEW YORK, Oct. 8, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB). Such investors are ...

GlobeNewsWire - 3 months ago

NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and ...

GlobeNewsWire - 3 months ago

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and...

Seeking Alpha - 5 months ago

Y-mAbs Is One To Accumulate Before PDUFA

Seeking Alpha - 5 months ago

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development an...

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development a...

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the second quar...

GlobeNewsWire - 5 months ago

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development an...

GlobeNewsWire - 6 months ago

NEW YORK, July 14, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development an...

GlobeNewsWire - 6 months ago

NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development an...

The Motley Fool - 6 months ago

While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.

Other stocks mentioned: ACAD
The Motley Fool - 7 months ago

This cancer-fighting biotech could have two approved drugs in the next year, and a whole lot more.

Seeking Alpha - 8 months ago

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

NEW YORK, April 24, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development ...

GlobeNewsWire - 9 months ago

NEW YORK, April 15, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development a...

Seeking Alpha - 10 months ago

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development an...

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development a...

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development a...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development a...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development a...

Seeking Alpha - 1 year ago

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development an...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development a...

Benzinga - 1 year ago

Y-mAbs Therapeutics, Inc (NASDAQ: YMAB), a thinly traded small-cap oncology-focused biopharma company, said in a Friday SEC filing that its omburtamab pre-BLA meeting with the FDA may now be d...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development a...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development a...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and co...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and co...

Benzinga - 1 year ago

Shares of Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) seem undervalued, given the market opportunities of the company’s core, late stage assets as well as upside potential from its label expansion...

GlobeNewsWire - 1 year ago

NEW YORK, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development an...

Seeking Alpha - 1 year ago

Y-mAbs Therapeutics' (YMAB) CEO Claus Moller on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Shares have risen by over 25% since IPO pricing in September of last year.

About YMAB

Y-mAbs Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab th... [Read more...]

Industry
Biotechnology
IPO Date
Sep 21, 2018
Stock Exchange
NASDAQ
Ticker Symbol
YMAB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is 60.11, which is an increase of 33.82% from the latest price.

Price Target
$60.11
(33.82% upside)
Analyst Consensus: Buy